Exelixis Stock Gets Weaker EPS Forecast from Zacks Research

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Zacks Research lowered their FY2027 earnings per share (EPS) estimates for shares of Exelixis in a research note issued to investors on Thursday, October 8th. Zacks Research analyst Team now expects that the biotechnology company will post earnings per share of $3.56 for the year, down from their prior estimate of $3.59. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Exelixis’ current full-year earnings is $3.19 per share. Zacks Research also issued estimates for Exelixis’ Q4 2027 earnings at $0.99 EPS.

Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Exelixis had a return on equity of 42.17% and a net margin of 35.33%. The company had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. During the same quarter in the previous year, the company posted $0.75 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis.

EXEL has been the topic of several other reports. Truist Financial raised their price target on Exelixis from $52.00 to $54.00 and gave the stock a “hold” rating in a research report on Wednesday, October 7th. UBS Group set a $55.00 price objective on Exelixis in a report on Monday, August 3rd. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. HC Wainwright reissued a “buy” rating and issued a $56.00 target price on shares of Exelixis in a research note on Thursday, July 2nd. Finally, Royal Bank Of Canada set a $51.00 target price on Exelixis and gave the stock a “sector perform” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $50.79.

Exelixis Trading Down 0.1%

Shares of NASDAQ EXEL opened at $59.82 on Monday. The firm has a market capitalization of $14.82 billion, a PE ratio of 18.81, a price-to-earnings-growth ratio of 1.78 and a beta of 0.47. Exelixis has a 1 year low of $33.76 and a 1 year high of $61.66. The firm’s 50-day moving average is $56.36 and its 200-day moving average is $52.41.

Insiders Place Their Bets

In other news, Director Mary Beckerle sold 9,812 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the transaction, the director owned 16,079 shares in the company, valued at $862,799.14. This represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Exelixis

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Exelixis during the 1st quarter worth approximately $27,000. Western Wealth Management LLC bought a new stake in shares of Exelixis in the 1st quarter valued at $29,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Exelixis during the 2nd quarter valued at $46,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Exelixis during the 2nd quarter valued at $57,000. Finally, Continuum Advisory LLC acquired a new position in shares of Exelixis during the 2nd quarter valued at $76,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

About Exelixis

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer. The company’s research and development activities are centered primarily on targeted therapies and other treatments for solid tumors.

Exelixis’ principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. The company also markets COMETRIQ, a cabozantinib formulation approved in the United States for progressive or metastatic medullary thyroid cancer.

Exelixis was founded in 1994 and is headquartered in Alameda, California.